Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan Effects on Renal Handling and Circulation During NO Inhibition
NCT01638663Phase 2Completed
- Sponsor
- Regionshospitalet Holstebro
- Start
- May 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tolvaptan in hyponatremia, cardiovascular disease (CVD) and nephropathy, sponsored by Regionshospitalet Holstebro. Primary endpoint: Free water clearance. Started May 2012; status: completed.
02
Drugs
tolvaptan
03
Conditions
hyponatremiacardiovascular disease (CVD)nephropathy
Beyond the preview
Go deeper on NCT01638663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01638663.